You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

Claims for Patent: 11,534,407


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,534,407
Title:Pharmaceutical compostion containing acetominophen and ibuprofen
Abstract:Solid oral dosage forms containing 325 mg of acetaminophen and 97.5 mg of ibuprofen or 500 mg of acetaminophen and 150 mg of ibuprofen, wherein the ibuprofen has a [D50] between 1 and 9 μm, are described.
Inventor(s):Maura Murphy, Matt Callahan
Assignee: AFT Pharmaceuticals Ltd
Application Number:US17/548,877
Patent Claims: 1. A tablet comprising 325 mg of acetaminophen and 97.5 mg of ibuprofen or 500 mg of acetaminophen and 150 mg of ibuprofen, wherein the ibuprofen has a [D50] between 2 and 8 μm, wherein the ibuprofen is prepared by a method comprising milling ibuprofen together with acetaminophen and a surfactant.

2. The tablet of claim 1, wherein the ibuprofen has a [D10] between 1 and 3 μm.

3. The tablet of claim 1, wherein the ibuprofen has a [D90] between 3 and 16 μm.

4. The tablet of claim 1, wherein the ibuprofen has a [D50] between 2 and 8 μm, a [D10] between 1 and 3 μm and a [D90] between 4 and 16 μm.

5. The tablet of claim 1 wherein the dissolution rate of ibuprofen in the solid oral dosage form is such that, when tested using USP Apparatus II (paddles) set to rotation speed of 50 rpm in 900 mL of 50 mM pH 5.8 phosphate buffer at 37 ° C., wherein 80% or more of the ibuprofen dissolves in 15 minutes or less.

6. The tablet of claim 5, wherein at least 85% to 95% of the ibuprofen dissolves in 15 minutes or less.

7. The tablet of claim 5, wherein at least 95% to 100% of the ibuprofen dissolves in 10 minutes or less.

8. The tablet of claim 1, wherein the milling is dry milling.

9. The tablet of claim 1, wherein the tablet is coated.

10. The tablet of claim 1, wherein the ibuprofen has [D90] to [D50] ratio that is between 4:1 and 1.5:1.

11. The tablet of claim 1, wherein the [D90] to [D50] ratio is between 3:1 and 1.5:1.

12. The tablet of claim 1, wherein the [D50] to [D10] ratio is between 4:1 and 1.5:1.

13. The tablet of claim 1, wherein the [D50] to [D10] ratio is between 3:1 and 1.5:1.

14. The tablet of claim 1, wherein the tablet is a coated tablet.

15. The tablet of claim 1, prepared by a process comprising milling a composition comprising 21-23% wt/wt ibuprofen and 73-75% wt/wt acetaminophen.

16. The table of claim 1, comprising 325 mg of acetaminophen and 97.5 mg of ibuprofen.

17. The tablet of claim 1, comprising 500 mg of acetaminophen and 150 mg of ibuprofen.

18. The tablet of claim 1, wherein the surfactant is sodium lauryl sulfate.

19. The tablet of claim 5, wherein 85% to 95% of the ibuprofen dissolves in 15 minutes.

20. The tablet of claim 5, wherein 95% to 100% of the ibuprofen dissolves in 10 minutes.

21. A method for treating pain comprising administering a dose of 1, 2 or 3 units of the tablet of claim 1 comprising 325 mg of acetaminophen and 97.5 mg of ibuprofen.

22. The method of claim 21, wherein the administration is 1, 2, 3 or 4 times daily.

23. A method for treating pain comprising administering a dose of 1 or 2 units of the solid oral dosage form of claim 1 comprising 500 mg of acetaminophen and 150 mg of ibuprofen.

24. The method of claim 23, wherein the administration is 1, 2, 3 or 4 times daily.

25. The method of claim 21, wherein the pain is mild to moderate acute pain.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.